

### Maximal mid-expiratory flow detects early lung disease in 1-antitrypsin deficiency

Stockley, James; Ismail, Asem M; Hughes, Siân M; Edgar, Ross; Stockley, Robert A; Sapey, Elizabeth

DOI:

[10.1183/13993003.02055-2016](https://doi.org/10.1183/13993003.02055-2016)

[10.1183/13993003.02055-2016](https://doi.org/10.1183/13993003.02055-2016)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Stockley, J, Ismail, AM, Hughes, SM, Edgar, R, Stockley, RA & Sapey, E 2017, 'Maximal mid-expiratory flow detects early lung disease in 1-antitrypsin deficiency', *The European respiratory journal*, vol. 49, no. 3, 1602055. <https://doi.org/10.1183/13993003.02055-2016>, <https://doi.org/10.1183/13993003.02055-2016>

[Link to publication on Research at Birmingham portal](#)

**Publisher Rights Statement:**

This is the peer reviewed version of the following article: James A. Stockley, Asem M. Ismail, Siân M. Hughes, Ross Edgar, Robert A. Stockley, Elizabeth Sapey, *European Respiratory Journal* 2017: 49, which has been published in final form at <https://doi.org/10.1183/13993003.02055-2016>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Checked 3/5/17

**General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

**Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1  
2  
3 **Maximal mid expiratory flow detects early lung disease in Alpha-1**  
4 **Antitrypsin Deficiency.**  
5  
6  
7

8  
9 Dr James A Stockley PhD<sup>1</sup>, Mr Asem M Ismail BSc<sup>2</sup>, Miss Siân M Hughes MSc<sup>3</sup>, Mr Ross  
10 Edgar BSc<sup>4</sup>, Professor Robert A Stockley DSc<sup>6,8</sup>, Dr Elizabeth  
11 Sapey PhD<sup>7,8</sup>  
12  
13

- 14  
15  
16 1. JAS. Department of Lung Function and Sleep, University Hospital Birmingham, Birmingham, UK  
17  
18 2. AMI, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK  
19  
20 3. SMH, Department of Lung Function and Sleep, University Hospital Birmingham, Birmingham, UK  
21  
22 4. RE, Department of Lung Function and Sleep, University Hospital Birmingham, Birmingham, UK  
23  
24 5. Author withdrew  
25  
26 6. RAS, Respiratory Medicine, University Hospital Birmingham, Birmingham, UK  
27  
28 7. ES, Corresponding Author. Institute of Inflammation and Ageing, Centre for Translational Inflammation  
29 Research, University of Birmingham, Edgbaston, Birmingham, UK, B15 2GW. Email: [e.sapey@bham.ac.uk](mailto:e.sapey@bham.ac.uk)  
30  
31 8. Joint senior authors  
32  
33  
34

35 **Take Home Message**  
36

37  
38 Mean mid-expiratory flow indicates early disease, worse health status and predicts decline in  
39 AATD patients without COPD.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Pathological studies suggest loss of small airways precedes airflow obstruction and emphysema in COPD. Not all Alpha 1 Anti-trypsin deficiency(AATD) patients develop COPD and measures of small airways function might be able to detect those at risk.

MMEF, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC ratio, health status, presence of emphysema (CT densitometry) and subsequent decline in FEV<sub>1</sub> were assessed in 196 AATD patients.

FEV<sub>1</sub>/FVC, FEV<sub>1</sub> %predicted and lung densitometry, related to MMEF %predicted ( $r^2=0.778$ ,  $p<0.0001$ ;  $r^2=0.787$ ,  $p<0.0001$ ,  $r^2=0.594$ ,  $p<0.0001$ , respectively) in a curvilinear fashion. Patients could be divided into those with normal FEV<sub>1</sub>/FVC and maximal mid-expiratory flow (MMEF)(Group 1), normal FEV<sub>1</sub>/FVC and reduced MMEF(Group 2) and those with spirometrically-defined COPD(Group 3). Patients in Group 2 had worse health status than Group 1 (Total SGRQ (median) 23.15 [IQR7.09-39.63] versus 9.67 [IQR 1.83-22.35];  $p=0.006$ ) and had a greater subsequent decline in FEV<sub>1</sub> (median change in FEV<sub>1</sub>=-1.09% predicted/year [IQR=-1.91--0.04] versus -0.04%predicted/year [IQR =-0.67-0.03];  $p=0.007$ ).

A reduction in MMEF is an early feature of lung disease in AATD and is associated with impaired health status and a faster decline in FEV<sub>1</sub>.

## Introduction

The early detection and prevention of COPD are key objectives both scientifically and clinically. COPD is defined physiologically by the presence of airflow obstruction ( $FEV_1/FVC$  ratio  $<70\%$ ) and disease severity is stratified by  $FEV_1$  impairment<sup>(1)</sup>, however, there is increasing recognition that  $FEV_1$  and  $FEV_1/FVC$  ratio lack sensitivity to identify early disease or patients at risk of subsequent decline without serial testing over a prolonged period of time<sup>(2, 3)</sup>. Therefore, there has been a revival of interest in assessing the small airways of the lungs. The cross-sectional micro-Computed Tomographic (CT) imaging studies of Hogg and colleagues<sup>(4, 5)</sup> reported major loss of small airways prior to the development of abnormal spirometry or emphysema in COPD patients. They hypothesised that reduced small airways function (by narrowing and reduction in number) precedes the decline in  $FEV_1$  and the development of emphysema in the very early stages of COPD. This is important as emphysema can be present with normal spirometry<sup>(6, 7)</sup>, is a predictor of mortality even in patients without COPD<sup>(8)</sup> and also relates to the subsequent decline in  $FEV_1$ <sup>(9, 10)</sup>, which itself is a major predictor of mortality for COPD patients<sup>(11)</sup> and may not be influenced by current inhaled therapies<sup>(12)</sup>.

Understanding the relationship of small airways dysfunction (SAD) to the presence and subsequent progression of lung disease may be of central importance in the early detection of COPD. However, only a proportion of smokers develop COPD<sup>(13)</sup> and only a proportion of patients with COPD develop emphysema<sup>(14)</sup> and so studying an unselected, “at risk” population to determine the relationship between SAD and the subsequent onset of emphysema and COPD would be demanding as a proof of principle study. Here, alpha-1 antitrypsin deficiency (AATD) serves as a useful model. AATD is a genetic susceptibility to COPD, where a significant proportion of smokers develop COPD at a younger age than non-AATD COPD, characterised by a predominant emphysema phenotype<sup>(15)</sup>.

Importantly a proportion of AATD patients who have never smoked also develop airflow obstruction and emphysema, although some do not<sup>(16)</sup> and currently we are unable to predict those at risk of decline. Family testing identifies siblings/progeny earlier in the disease process, often before COPD and emphysema are detectable, allowing the whole time course of the disease process to be observed.

1  
2  
3 We hypothesised that a proportion of never smoking AATD patients would have evidence of  
4 SAD without COPD, and those patients would experience more lung symptoms and would be  
5 at greater risk of subsequent progression.  
6  
7

8  
9 The current study aimed to determine the relationship of the maximal mid-expiratory flow  
10 (MMEF- a spirometric parameter that when reduced is suggestive of SAD<sup>(17)</sup> and is readily  
11 available from the flow volume loop) to FEV<sub>1</sub> and FEV<sub>1</sub>/FVC ratio, health status and CT  
12 defined emphysema. Of particular interest were subjects with both an FEV<sub>1</sub> and FEV<sub>1</sub>/FVC  
13 ratio within the “normal range” to determine whether the presence of SAD might precede  
14 conventional airflow obstruction. In addition, follow up spirometry was analysed to relate the  
15 initial presence of SAD to subsequent decline in FEV<sub>1</sub>. Percent predicted values were  
16 utilised as these are already adjusted for age, sex, height and ethnicity; thus accounting for  
17 these major determinants of lung function. In this proof of principle study, only never  
18 smoking AATD patients were included to determine the natural history of this disease and  
19 avoid the potential impact of variable smoking histories on lung physiology.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **Materials and Methods**

### 31 *Study Subjects*

32  
33  
34  
35  
36 ADAPT includes the UK registry for individuals with AATD. The programme was approved  
37 by the South Birmingham Research and Ethics Committee (Ref number; 3359a) and all  
38 patients provided written, informed consent. Patients were recruited either through medical  
39 referral (index) or family screening (non-index). For this study, >95% of index patients were  
40 screened for AATD due to a past medical history of respiratory symptoms, including an  
41 awareness of breathlessness greater than expected, cough or recurrent chest infections. Less  
42 than 5% of patients were identified by the presence of abnormal and unexplained liver  
43 function tests but not liver disease. Patients with significant structural lung disease (such as  
44 bronchiectasis) were excluded. Asthma is known to effect small airways function<sup>(18)</sup> and this  
45 was specifically screened for symptomatically as previously described<sup>(19)</sup>.  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Patients participating in this study had annual assessments that included post-bronchodilator  
56 full lung function, blood biochemistry and haematology, and health status using the St.  
57  
58  
59  
60

1  
2  
3 George's Respiratory Questionnaire (SGRQ). Patients also had a high resolution CT scan at  
4 baseline for qualitative and quantitative assessment where this had not been undertaken by  
5 the referring clinicians.  
6  
7

### 8 9 10 *Methods*

11  
12 Initial baseline data was collected for lifelong never-smokers with a PiZZ AATD genotype.  
13 Measures of lung function were assessed on the same day as the clinical and health status  
14 data. Spirometry data included FEV<sub>1</sub>, FEV<sub>1</sub>/FVC and MMEF. FEV<sub>1</sub> and MMEF were  
15 expressed as % predicted to differentiate between natural decline in lung function due to  
16 ageing (where absolute values decrease but % predicted remains stable) and decline due to  
17 disease (where both absolute and % predicted values decrease). The FEV<sub>1</sub>/FVC ratio was  
18 expressed as a percentage and the gas transfer coefficient (Kco) was documented as %  
19 predicted.  
20  
21  
22  
23  
24  
25  
26

27 MMEF was chosen as it is the most readily accessible spirometric parameter that may relate  
28 to small airways function. However, the utility of MMEF in this carefully selected group of  
29 AATD patients is unclear. In the current study a cut-off of 80% predicted was pragmatically  
30 chosen for MMEF as this is compatible with previous studies (for example,<sup>(20, 21)</sup>) and meant  
31 that those described as “normal” for the purposes of this study were less likely to include  
32 patients with small airways dysfunction.  
33  
34  
35  
36  
37

38 Decline in lung function was primarily determined by the change in % predicted for age, sex,  
39 height, and ethnicity using linear regression determined for all annual data points (provided  
40  $\geq 4$ ) for each patient. Rapid decliners were defined as those whose lung function decline  
41 (FEV<sub>1</sub> change) was  $> -1.0\%$  predicted per year as described previously<sup>(22)</sup>.  
42  
43  
44  
45  
46

47 All lung function tests were performed on Jaeger Masterscreen Pro lung function system  
48 (Jaeger Ltd, Hochberg, Germany) according to the Association for Respiratory Technology  
49 and Physiology/British Thoracic Society guidelines for quality control<sup>(23)</sup>. Predicted values  
50 for all tests were calculated from the European Community for Steel and Coal reference  
51 equations<sup>(24)</sup>.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 For high resolution CT scans (GE Prospeed Scanner; General Electrical Medical Systems;  
4 Milwaukee, WI), 1 mm slices were taken at 10 mm intervals through the thorax at full  
5 inspiration. Mean lung density was recorded in Hounsfield Units (HU), with a value less than  
6 -950 HU used as a threshold consistent with the presence of macroscopic emphysema<sup>(25)</sup>. CT  
7 data was included only where it was available and suitable for quantifiable analysis at the  
8 start of the study (at the time of baseline MMEF and lung function data) and is expressed as  
9 the PD15 (percentile point indicating the density of the lowest 15% of the voxels).  
10  
11  
12  
13  
14  
15

### 16 *Analysis*

17  
18 The main outcome measures included the spirometric parameters FEV<sub>1</sub>, FEV<sub>1</sub>/FVC and  
19 MMEF. Secondary outcome measures included Kco and lung densitometry. T-tests, Mann-  
20 Whitney U tests and Kruskal Wallis were used to compare categories and spline modelling  
21 was used to determine the strength of any relationship. Chi-Squared tests were used to  
22 compare categorical data between groups. The predicted positive and negative value of  
23 MMEF to detect a rapid decline in lung function in patients with no physiological evidence of  
24 COPD was calculated using standard methods<sup>(26)</sup>. A p value of <0.05 was taken to be  
25 statistically significant for all analyses.  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Results**

35  
36 A total of 196 never-smoking PiZZ AATD patients were identified and divided into three  
37 physiological groups; Group 1 (n=43) had FEV<sub>1</sub>/FVC>70% and MMEF≥80% predicted (no  
38 SAD, no COPD); Group 2 (n=40) had FEV<sub>1</sub>/FVC>70% and MMEF<80% predicted (SAD  
39 but no COPD) and Group 3 (n=113) had FEV<sub>1</sub>/FVC<70%, thus meeting physiological  
40 diagnostic criteria for COPD<sup>(27)</sup>. No patients had an MMEF≥80% predicted and evidence of  
41 COPD. Demographic data and lung function of patients in the three physiological groups are  
42 shown in Table 1. There were a greater proportion of females in Group 2 (SAD but no  
43 COPD) compared to Group 1 (no SAD and no COPD, p=0.035) and Group 3 (COPD,  
44 p=0.002). The average age increased across groups with Group 1 patients being the youngest  
45 (p<0.001 for the difference across all groups). There was a greater proportion of index  
46 patients in Group 3 compared to Group 1 (p<0.001) and Group 2 (p<0.001). The prevalence  
47 of asthma was approximately 10% across this population and there were no differences in  
48 prevalence between groups (see table 1).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Group 2 (SAD, no COPD) had worse lung function than Group 1 (no SAD, no COPD), including FEV<sub>1</sub>% predicted (p=0.011), FEV<sub>1</sub>/FVC (p=0.009), Kco% predicted (p=0.055) and, by definition, MMEF% predicted (p<0.001). In turn, Group 3 (COPD) had worse lung function than Group 2 (p<0.001 for all indices, including FEV<sub>1</sub>% predicted, FEV<sub>1</sub>/FVC, Kco % predicted and MMEF % predicted).

**Table 1 – Demographic Data**

Variables	Group 1	Group 2	Group 3
Number of Patients	43	40	113
Males : Females	20 : 23	10 : 30 †¥	60 : 53
Age (yr)	38.1 ± 13.1	49.1 ± 13.1 †	60.4 ± 9.4 †§
Index : Non-Index	20 : 23	21 : 19	96 : 17 †§
FEV <sub>1</sub> % Predicted	118.7 ± 13.7	105.6 ± 15.6 †	65.0 ± 23.7 †§
FVC (%)	114.8 (107.4 – 129.3)	109.8 (99.4 – 126.9)	117.9 (100.4 – 135.0)
FEV <sub>1</sub> /FVC (%)	86.0 ± 5.7	79.2 ± 5.5 †	44.6 ± 12.7 †§
MMEF % Predicted	110.7 ± 19.7	60.1 ± 12.6 †	17.5 ± 11.4 †§
Kco % Predicted	93.4 ± 18.5	83.5 ± 15.5	67.3 ± 20.7 †§
Δ FEV <sub>1</sub> (ml/yr)	-27.9¥ § (-49.1 - -4.87)	-52.7 † (-78.5 - -22.7)	-57.3 † (-83.3 - -27.3)
Serum AATD level	4.4 (3.05 – 4.98)	3.9 (2.8 – 4.6)	4.2 (3.28 – 5.03)
Asthma, n (%)	4 (9.3)	4 (10)	5 (4.4)

Patient demographics are summarised for the 3 groups with mean ± SD unless otherwise stated. Change in FEV<sub>1</sub> is the decline based on 4 measurements taken over 3 years and expressed as median and range. AAT level is serum level (measured in umol/l and is given as the median and range. Asthma is the number in each group with a Consultant physician confirmed diagnosis. Differences between groups are indicated by the symbols; † Significantly different from Group 1; § Significantly different from Group 2; ¥ Significantly different from Group 3

#### *Relationship between lung function measurements*

There was a strong ( $r^2=0.778$ ,  $p<0.0001$ ) relationship between the FEV<sub>1</sub>/FVC ratio and MMEF % predicted (Figure 1) and for FEV<sub>1</sub> % predicted and MMEF % predicted ( $r^2=0.787$ ,  $p<0.0001$ ). There was a weaker though significant relationship ( $r^2=0.198$ ,  $p<0.0001$ ) between Kco % predicted and MMEF % predicted.

#### *Health Status*



1  
2  
3 Health status was assessed at baseline using the SGRQ. The median total SGRQ score was  
4 greater (indicating worse health status) in Group 2 (SAD, no COPD: median 23·15, IQR  
5 7·09-39·63) than Group 1 (no SAD, no COPD: median 9·67, IQR 1·83-22·35,  $p=0·006$ )  
6 (Figure 2A). The same trend was seen for the individual domains with a median of 29·49,  
7 IQR 5·96-51·00 and 5·84, IQR 0·00-26·97, respectively for activity ( $p<0·001$ ) (Figure 2B)  
8 and 15·38, IQR 1·90-26·40 and 3·89, IQR 0·00-11·60, respectively for disease impact  
9 ( $p=0·028$ ) (Figure 2C). However, there was no significant difference ( $p>0·05$ ) between  
10 SGRQ symptom scores for Group 1 (median 29·17, IQR 5·23-45·61) and Group 2 (median  
11 37·77, IQR 17·07-59·59) (Figure 2D). SGRQ scores were even greater in Group 3 (COPD)  
12 compare to Group 2 for total score (median 38·25, IQR 27·06-53·72,  $p<0·0001$ ), activity  
13 (median 53·62, IQR 35·60-66·19,  $p<0·0001$ ), disease impact (median 24·80, IQR 14·11-  
14 40·50,  $p<0·001$ ) and symptoms (median 54·74, IQR 42·38-68·57,  $p=0·002$ ).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *Lung Function Decline*

27  
28 The rate of FEV<sub>1</sub> decline (% predicted) following baseline measurement was measured over  
29 at least 3 years to ensure at 4 or more data points for analysis<sup>(16)</sup>. The median decline was  
30 greater in Group 2 (SAD, no COPD: median change in FEV<sub>1</sub> -1·09% predicted/year, IQR -  
31 1·91 to -0·04) than Group 1 (no SAD, no COPD: median change in FEV<sub>1</sub> -0·04%  
32 predicted/year, IQR -0·67 to 0·03) ( $p=0·007$ ). The median decline in FEV<sub>1</sub> in Group 3  
33 (COPD) was similar ( $p>0·05$ ) to that in Group 2 (-1·41% predicted/year, IQR -2·27 to -0·22)  
34 as shown in Figure 3. The decline in FEV<sub>1</sub> expressed as ml/year is shown in Table 1.  
35  
36  
37  
38  
39

40 85% of AATD patients without COPD and an MMEF  $\geq 80\%$  predicted did not subsequently  
41 decline rapidly (an 85% negative predictive value). The positive predictive value was 57%.  
42  
43  
44  
45

### 46 *CT Densitometry*

47  
48 Quantitative CT densitometry was available for 109 patients. There was a significant  
49 relationship of mean lung density in Hounsfield Units (HU) to MMEF % predicted (Figure 4)  
50 ( $r^2=0·594$ ,  $p<0·0001$ ). Although numbers are low, all patients with MMEF  $> 80\%$  predicted  
51 had no evidence of emphysema ( $n = 3$ , Median PD15 (Interquartile range, IQR) -904·6 (-  
52 922·76 - -876·75). 11 patients had a reduced MMEF ( $<80\%$  predicted) with the PD15 above  
53 the -950 HU threshold (median PD15 (IQR); -902·8(-913·05 - -873·35), with no macroscopic  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 emphysema. 95 patients had macroscopic emphysema (determined as the PD15 <-950HU,  
4 Median PD15 (IQR) -957.93 (-968-63—942.22) and all of these had severely reduced MMEF  
5 ( $\leq 20\%$  predicted).  
6  
7

## 8 9 10 11 **Discussion**

12  
13 The current paper describes unique data from a cohort of never-smoking individuals with  
14 AATD who have never received augmentation therapy, showing that subjects without  
15 spirometric evidence of COPD include some with reduced values for MMEF (defined here as  
16 <80% predicted), potentially suggestive of impaired small airways function. Those with an  
17 MMEF <80% predicted already have evidence of reduced health status despite their FEV<sub>1</sub>  
18 and FVC being within the normal range and subsequently demonstrated a more rapid decline  
19 in FEV<sub>1</sub>.  
20  
21  
22  
23  
24

25  
26 MMEF appears of questionable value in an unselected population<sup>(28)</sup>, but the usefulness of a  
27 spirometric parameter maybe different in different populations. The subjects included in the  
28 present work are never smoking AATD PiZZ patients, a highly selected population, and these  
29 data suggest MMEF may be useful to identify subgroups in this cohort with specific  
30 characteristics and to predict disease progression.  
31  
32  
33  
34  
35

36 Differences in the shape of the forced expiration curve have been noted as early as 1976,  
37 where a “kink” in the spirogram was associated with a higher prevalence of emphysema in  
38 patients with airflow obstruction<sup>(29)</sup> and lower maximal expiratory flow measurements at  
39 75%, 50% and 25% of FVC were seen in PiMZ AATD non-smokers compared to PiMM  
40 patients<sup>(30)</sup>. Since this time there has been little further information about small airways  
41 function in AATD although a recent study demonstrated an overall trend for more rapid  
42 decline in MMEF in PiMZ individuals over 11 years compared to those with the PiMM and  
43 PiMS phenotypes, whilst FEV<sub>1</sub> and FEV<sub>1</sub>/FVC declined at the same rate in all groups  
44 (although values were expressed as absolute change and not % predicted)<sup>(31)</sup>. Studies of small  
45 airway function in non AATD COPD are also limited. Gold 0 COPD patients (those with a  
46 normal FEV<sub>1</sub>/FVC but considered “at risk”) had lower MMEF %predicted than normal  
47 subjects<sup>(32)</sup>. In addition, MMEF/FVC has been used as a diagnostic parameter for early stage  
48 COPD in smokers with otherwise normal spirometry<sup>(33)</sup>. Collectively, these studies support  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 the concept that MMEF may be useful in detecting early pathological changes in COPD and  
4 support our findings in AATD. However the utility of MMEF or other potential measures of  
5 small airways function would also need to be assessed in a non-AATD COPD cohort and  
6 patients at risk of COPD to determine more generalised utility.  
7  
8

9  
10  
11 What constitutes an abnormal MMEF is uncertain. The normal range for MMEF based on  
12 standardised residuals/z-scores is broad <sup>(34)</sup> and in a general population reporting MMEF  
13 using z-scores is not clinically useful over and above the traditional spirometric parameters  
14 such as FEV<sub>1</sub>/FVC<sup>(28)</sup>. In the current study a cut-off of 80% predicted was pragmatically  
15 chosen for MMEF as this is compatible with previous studies (for example,<sup>(20, 21)</sup>) but patterns  
16 were similar if a cut off of 75% or 70% predicted were chosen. Moreover, choosing an 80%  
17 predicted cut-off for MMEF means that a greater number of patients with SAD are likely to  
18 be included in Group 2. The 70% fixed FEV<sub>1</sub>/FVC ratio definition of COPD was also chosen  
19 to align this paper with the current GOLD strategy and enable easier comparison with other  
20 published work in this area.  
21  
22  
23  
24  
25  
26  
27  
28

29  
30 The average age of the patients studied here ranged from 40 years for those in Group 1 to 50  
31 years for those with MMEF values suggestive of SAD (Group 2) and 60 for those with COPD  
32 (Group 3). Lung function data, however, is presented as % predicted (thereby accounting for  
33 age differences) and thus the decline in lung function could relate to the early stages of  
34 airway remodelling in Group 2 that precede more significant airflow limitation associated  
35 with COPD (Group 3). There was also a trend towards lower gas transfer in Group 2, which  
36 may reflect early emphysematous change. Patients in Group 2 (SAD, no COPD) also had  
37 impairment of health status compared to those with higher MMEF (Group 1). Although this  
38 may be at variance with earlier work in AATD that used a different symptom  
39 questionnaire<sup>(35)</sup> it is consistent with more recent work that has shown patients with GOLD  
40 Stage 0 COPD<sup>(27)</sup> can also have reduced quality of life<sup>(36)</sup>. The presence of worse symptoms  
41 in patients with mild spirometric COPD has also been shown in our previous work<sup>(37)</sup> and,  
42 collectively, the data in the current study supports a subtle decline in health status in tandem  
43 with early deterioration in lung physiology. Prospective studies would be needed to confirm  
44 this.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55  
56 The predictive value of MMEF in this study suggests it may be an effective screening tool to  
57 select those most at risk of a fast decline in this group of patients. If this were confirmed in  
58  
59  
60

1  
2  
3 prospective studies, these tests might identify a physiological subgroup (with evidence of  
4 SAD) that require closer monitoring, and perhaps earlier interventions when considering  
5 suitability for future therapeutic trials (such as alpha-1 antitrypsin augmentation). There are  
6 other tests of small airways function but MMEF was chosen in this proof of principle study as  
7 it is readily available in most physiology centres. Prospective studies might identify even  
8 more informative measures.  
9  
10  
11  
12

13  
14 From a pathophysiological viewpoint, the data provide support for the cross-sectional studies  
15 of Hogg and colleagues<sup>(4)</sup>. Observational studies of lung specimens from patients with COPD  
16 (10 of whom had features typical of AATD—panlobular emphysema, younger and lower  
17 smoking history) and emphysema has highlighted major loss of small airways in the absence  
18 of emphysema, leading to the hypothesis that this is a precursor of alveolar destruction.  
19 Currently, pathological changes cannot be studied prospectively but the physiological data  
20 presented here is consistent with this concept. A proportion of our patients underwent  
21 quantitative CT scan density analysis at baseline and there was a relationship to MMEF  
22 values. Density relationships to the presence of emphysema have been studied extensively in  
23 the past and the best data compared to pathological specimens remains that by Gevenois and  
24 his colleagues<sup>(38)</sup> who determined that a threshold of -950HU showed the best correlation  
25 with emphysema. Our data was analysed as the PD15 which is used in most modern  
26 publications and reflects the threshold of the least dense 15% of voxels. It is therefore not  
27 entirely comparable with the pathological threshold described by Gevenois which indicated  
28 <7% of voxels below this threshold, but is similar to the values of <10%<sup>(39)</sup> and <13%<sup>(40)</sup>  
29 found in normal subjects, and all subjects with PD15 below this threshold in our study had  
30 marked impairment of MMEF. Importantly, there was a significant proportion of patients  
31 with reduced MMEF who had a PD15 well above this threshold, suggesting the presence of  
32 SAD without emphysema. As patients with AATD who develop COPD almost invariably  
33 have emphysema, the data suggest significant loss of and/or impairment of airflow in the  
34 small airways does occur before emphysema becomes apparent. The age difference between  
35 our physiological groups also supports this as a natural temporal progression pathologically  
36 and confirms the importance to express values as % predicted in such studies. However, it  
37 should be noted that not all patients with AATD develop COPD and emphysema<sup>(25)</sup> and early  
38 evidence of SAD may differentiate these diverse outcomes. Our current data reflects an  
39 average result for the whole lung rather than regional assessment of the upper and lower  
40 zones which may more closely reflect different distribution patterns of emphysema known to  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 have different physiological effects especially in established disease<sup>(41)</sup>. This would be  
4 important for definitive interpretation in future prospective studies of AATD patients without  
5 COPD  
6  
7

8  
9  
10 Apart from age and lung function, the only other clear differences between the groups were  
11 sex in Group 2 (with a higher percentage of females having an MMEF  $\leq 80\%$  predicted  
12 without COPD) and a higher percentage of non-index cases in Groups 1 and 2. Index status is  
13 to be expected, since family screening tends to identify patients with more preserved lung  
14 function than found in index cases<sup>(42)</sup>. It is unclear why more females were present in Group  
15 2 than Group 1 or 3. There is no published literature to suggest AATD females experience a  
16 faster decline than men. While this could reflect sampling bias, this observation requires  
17 follow up to determine its significance. Other studies have also looked at sex and respiratory  
18 symptoms, small airways responses and hyper-responsiveness and there are conflicting  
19 results (for example,<sup>(43, 44)</sup>); this subject appears far less understood and far more complex  
20 than initially thought but we have utilised percent predicted results in our analysis as these  
21 take into consideration sex and height differences in lung function to try and overcome the  
22 inherent size difference in the lungs of our patients.  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 The current study has excluded current or ex-smokers, which is both a strength and a  
34 weakness. Studying never smokers allows the natural history of AATD alone to be defined as  
35 smoking accelerates the development of COPD in AATD and a faster pathological  
36 progression. In addition most individuals stop smoking on diagnosis of AATD thereby  
37 altering the natural history. Our current cohort of over 900 AATD subjects and the group  
38 with normal spirometry includes no active smokers and only 21 ex-smokers; too small a  
39 proportion to analyse meaningfully. This study does not include information of passive  
40 smoke exposure or occupational history. While both factors may affect small airways  
41 function and lung development in childhood in some patients with AATD, the main question  
42 addressed here is whether current evidence of small airways dysfunction might impact on  
43 health status or subsequent FEV<sub>1</sub> decline in this population. Thus whatever the preceding  
44 time course involved, tests consistent with SAD act as a marker of faster subsequent decline.  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 MMEF is affected by loss of elastic recoil (seen in emphysema), which results in expiratory  
55 airflow limitation due to dynamic airways compression. However, we have shown that a  
56 number of patients have severely reduced MMEF but no evidence of emphysema on CT scan.  
57  
58  
59  
60

1  
2  
3 We suggest that this could reflect small airways dysfunction but interpretation without  
4 pathology will require a more comprehensive long term study.  
5  
6

7  
8 In summary, the implications of our findings in AATD are two-fold. First, we now have  
9 physiological evidence to support the previous histological studies that SAD is an early  
10 feature of lung disease in AATD and precedes the development of emphysema and COPD<sup>(5)</sup>.  
11 MMEF % predicted may be a useful marker of early disease in these patients.  
12

13  
14 Second, AATD patients with a reduced MMEF appear more likely to be “rapid decliners”<sup>(16)</sup>  
15 than those with preserved small airway function. Therefore, MMEF may be a more sensitive  
16 physiological marker of AATD patients at risk of decline than FEV<sub>1</sub>/FVC. There are also  
17 potential implications in non AATD-COPD, where re-evaluation of MMEF% predicted may  
18 provide a screening tool to identify patients at risk of developing emphysema and COPD  
19 prior to changes in FEV<sub>1</sub> and FEV<sub>1</sub>/FVC ratio.  
20  
21  
22  
23  
24

## 25 26 **Figure legends**

### 27 28 **FIGURE 1.**

29 FEV<sub>1</sub>/FVC ratio is plotted against MMEF % predicted. Each point represents data from a  
30 single patient (n=196) with all measurements taken on the same day. Groups 1, 2 and 3 are  
31 highlighted.  
32  
33  
34

### 35 36 **FIGURE 2.**

37 The charts show median, IQR and minimum/maximum bars for total SGRQ scores (A) and  
38 individual domain scores for activity (B), disease impact (C) and symptoms (D) for Groups 1,  
39 2 and 3. P values are shown for each comparison.  
40  
41  
42  
43

### 44 45 **FIGURE 3.**

46 The chart shows median, IQR and minimum/maximum bars in the annual change in FEV<sub>1</sub>  
47 (expressed as % predicted) for Groups 1, 2 and 3. Values were calculated from the regression  
48 line of annual serial measurements of 4 data points or more. A lower value indicates a faster  
49 rate of decline. The median FEV<sub>1</sub> percent predicted decline in Group 1 was approximately  
50 zero, suggesting these patients experienced an FEV<sub>1</sub> decline in keeping with that expected  
51 with age alone. Patients within Groups 2 and 3 experienced a decline in FEV<sub>1</sub> greater than  
52 seen with age alone, suggesting disease progression.  
53  
54  
55  
56  
57  
58  
59  
60

**FIGURE 4.**

The chart shows mean lung density (HU) versus MMEF % predicted. Each point represents data from a single patient (n=109). Patients with reduced MMEF (<80% predicted) but a lung density above that typical of macroscopic emphysema (>950 HU) are shown by the shaded area.

*Role of the Funding Source*

The Alpha-1 Foundation supplied the core project funding and CSL Behring provided monies in the form of non-commercial project grant funding to assist with data base analysis, but had no role in study design, data collection, analysis, interpretation, or manuscript production.

*Author contributions.*

JAS conducted tests of physiology, analysed and prepared the manuscript, AI, SH and RE helped collate clinical information and undertook some aspects of analysis. BGC oversaw all lung physiology, data interpretation and assisted with manuscript preparation. RAS and ES designed and coordinated studies, assisted with data interpretation and finalised the manuscript.

## References

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS. Global Strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med.* 2001;163:1256 - 76.
2. Pennock BE, Rogers RM, McCaffree DR. CHanges in measured spirometric indices. what is significant? *Chest.* 1981;80(1):97-9.
3. Herpel LB, Kanner RE, Lee SM, Fessler HE, Sciruba FC, Connett JE, et al. Variability of Spirometry in Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine.* 2006;173(10):1106-13.
4. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-Airway Obstruction and Emphysema in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine.* 2011;365(17):1567-75.
5. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine.* 2004;350(26):2645-53.

- 1  
2  
3 6. Koo HK, Jin KN, Kim DK, Chung HS, Lee CH. Association of incidental emphysema with  
4 annual lung function decline and future development of airflow limitation. *Int J Chron Obstruct*  
5 *Pulmon Dis.* 2016;11:161-6.  
6
- 7 7. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, et al. Characterisation of  
8 phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. *Thorax.*  
9 2007;62(11):932-7.  
10
- 11 8. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright PL, Kawut SM, et al. Association  
12 Between Emphysema-like Lung on Cardiac Computed Tomography and Mortality in Persons Without  
13 Airflow Obstruction A Cohort Study Emphysema-like Lung on CT and All-Cause Mortality. *Annals of*  
14 *Internal Medicine.* 2014;161(12):863-73.  
15
- 16 9. Mohamed Hoesein FA, de Hoop B, Zanen P, Gietema H, Kruitwagen CL, van Ginneken B, et  
17 al. CT-quantified emphysema in male heavy smokers: association with lung function decline. *Thorax.*  
18 2011;66(9):782-7.  
19
- 20 10. Nishimura M, Makita H, Nasuhara Y, Hizawa N, Betsuyaku T. Phenotype Characterization  
21 Based upon High-Resolution Computed Tomography Findings and Reversibility of Airflow  
22 Limitation in Chronic Obstructive Pulmonary Disease. *Proceedings of the American Thoracic*  
23 *Society.* 2006;3(6):544-.  
24
- 25 11. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, et al. CT scan findings of  
26 emphysema predict mortality in COPD. *Chest.* 2010;138(3):635-40.  
27
- 28 12. Enright P. HRCT-defined emphysema is not COPD to be treated with inhalers. *Thorax.*  
29 2014;69(5):401-2.  
30
- 31 13. Lundbäck B, Lindberg A, Lindström M, Rönmark E, Jonsson AC, Jönsson E, et al. Not  
32 15 But 50% of smokers develop COPD?—Report from the Obstructive Lung Disease in Northern  
33 Sweden Studies. *Respiratory Medicine.* 2003;97(2):115-22.  
34
- 35 14. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al.  
36 Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res.* 2010;11:122.  
37
- 38 15. Piitulainen E, Montero LC, Nystedt-Düzakin M, Stoel BC, Sveger T, Wollmer P, et al. Lung  
39 Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls  
40 at 35 Years of Age. *COPD: Journal of Chronic Obstructive Pulmonary Disease.* 2015;12(2):162-7.  
41
- 42 16. Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-  
43 antitrypsin deficiency: a need for patience in order to provide patient centered management? *Int J*  
44 *Chron Obstruct Pulmon Dis.* 2016;11:1745-56.  
45
- 46 17. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. *European*  
47 *Clinical Respiratory Journal; Vol 1 (2014) incl Supplements.* 2014.  
48
- 49 18. Bjermer L. The role of small airway disease in asthma. *Current Opinion in Pulmonary*  
50 *Medicine.* 2014;20(1):23-30.  
51
- 52 19. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of  
53 the new GINA strategy: a roadmap to asthma control. *Eur Respir J.* 2015;46(3):622-39.  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 20. Burki NK, Dent MC. The forced expiratory time as a measure of small airways resistance. .  
4 Clin Sci Mol Med. 1976;51(1):53 - 8.  
5
- 6 21. Marseglia GL, Cirillo I, Vizzaccaro A, Klersy C, Tosca MA, La Rosa M, et al. Role of forced  
7 expiratory flow at 25-75% as an early marker of small airways impairment in subjects with allergic  
8 rhinitis. Allergy Asthma Proc. 2007;28(1):74-8.  
9
- 10 22. Stockley RA, Miravittles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin  
11 deficiency: towards a personalised approach. Orphanet Journal of Rare Diseases. 2013;8(1):149.  
12
- 13 23. ARTP Handbook. The ARTP Practical Handbook of Respiratory Function Testing.  
14 <http://www.artp.org.uk/en/publications/artp-part-1-handbook.cfm>. 2003;2nd Edition.  
15
- 16 24. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes  
17 and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests,  
18 European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur  
19 Respir J Suppl. 1993;16:5-40.  
20
- 21 25. Gevenois PA, Yernault JC. Can computed tomography quantify pulmonary emphysema? Eur  
22 Respir J. 1995;5:843-8.  
23
- 24 26. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using  
25 sensitivity, specificity and predictive values. Indian Journal of Ophthalmology. 2008;56(1):45-50.  
26
- 27 27. Global Initiative for chronic obstructive lung disease. Guidelines and resources.  
28 <http://www.goldcopd.com/index>. 2007.  
29
- 30 28. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and  
31 FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051-8.  
32
- 33 29. Saltzman HP, Ciulla EM, Kuperman AS. The spirographic "kink". A sign of emphysema.  
34 Chest. 1976;69(1):51-5.  
35
- 36 30. Hall WJ, Hyde RW, Schwartz RH, Mudholkar GS, Webb DR, Chaubey YP, et al. Pulmonary  
37 abnormalities in intermediate alpha-1-antitrypsin deficiency. J Clin Invest. 1976;58(5):1069-77.  
38
- 39 31. Thun GA, Ferrarotti I, Imboden M, Rochat T, Gerbase M, Kronenberg F, et al. SERPINA1  
40 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. PLoS One.  
41 2012;7(8):e42728.  
42
- 43 32. Tsushima K, Sone S, Yoshikawa S, Furuya S, Yasuo M, Suzuki T, et al. Clinical differences  
44 in the Global Initiative for Chronic Obstructive Lung Disease Stage 0. Respiratory  
45 Medicine;100(8):1360-7.  
46
- 47 33. Mirsadraee M, Boskabady MH, Attaran D. Diagnosis of chronic obstructive pulmonary  
48 disease earlier than current Global Initiative for Obstructive Lung Disease guidelines using a feasible  
49 spirometry parameter (maximal-mid expiratory flow/forced vital capacity). Chronic Respiratory  
50 Disease. 2013;10(4):191-6.  
51
- 52 34. Birath G, Keielimer I, Sandavist L. Spirometric studies in normal subjects. Ventilatory  
53 capacity tests in adults. Acta Med Scand. 1963;173:193 - 8.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 35. Seersholm N, Kok-Jensen A. Clinical features and prognosis of life time non-smokers with  
4 severe alpha 1-antitrypsin deficiency. *Thorax*. 1998;53(4):265-8.  
5  
6 36. Maleki-Yazdi MR, Lewczuk CK, Haddon JM, Choudry N, Ryan N. Early Detection and  
7 Impaired Quality of Life in COPD GOLD Stage 0: A Pilot Study. *COPD: Journal of Chronic*  
8 *Obstructive Pulmonary Disease*. 2007;4(4):313-20.  
9  
10 37. Ward H, Turner AM, Stockley RA. Spirometric and gas transfer discordance in Alpha-1-anti  
11 trypsin Deficiency: Patient characteristics and progression *Chest*. 2014;145(6):1316-24.  
12  
13 38. Geveno PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, et al.  
14 Comparison of computed density and microscopic morphometry in pulmonary emphysema. *Am J*  
15 *Respir Crit Care Med*. 1996;154(1):187-92.  
16  
17 39. Mitsunobu F, Mifune T, Ashida K, Hosaki Y, Tsugeno H, Okamoto M, et al. Influence of age  
18 and disease severity on high resolution CT lung densitometry in asthma. *Thorax*. 2001;56(11):851-6.  
19  
20 40. Regan EA, Lynch DA, Curran-Everett D, et al. CLinical and radiologic disease in smokers  
21 with normal spirometry. *JAMA Internal Medicine*. 2015;175(9):1539-49.  
22  
23 41. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of Emphysema Distribution in  $\alpha$ 1-  
24 Antitrypsin Deficiency Influences Lung Function Impairment. *American Journal of Respiratory and*  
25 *Critical Care Medicine*. 2004;170(11):1172-8.  
26  
27 42. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotypic  
28 Differences in Alpha 1 Antitrypsin-Deficient Sibling Pairs May Relate to Genetic Variation. *COPD:*  
29 *Journal of Chronic Obstructive Pulmonary Disease*. 2008;5(6):353-9.  
30  
31 43. Leynaert B, Bousquet J, Henry C, Liard R, Neukirch F. Is bronchial hyperresponsiveness  
32 more frequent in women than in men? A population-based study. *Am J Respir Crit Care Med*.  
33 1997;156(5):1413-20.  
34  
35 44. Cohen J, Douma WR, Ten Hacken NH, Oudkerk M, Postma DS. Physiology of the small  
36 airways: A gender difference? *Respir Med*. 2008;102(9):1264-71.  
37  
38  
39  
40  
41  
42  
43

#### Declaration of Interests

44 JAS, AMI, SMH, RE, BCC and ES have no conflicts of interest to declare. RAS has  
45 participated on Ad boards for Boehringer Ingelheim, Zealand, Dyax, Chiesi, AstraZeneca and  
46 CSL Behring and has non-commercial grant income from CSL Behring.  
47  
48  
49  
50

#### Acknowledgements

51 The authors would like to thank patients with AATD for taking part in this study, Mrs. Diane  
52 Griffiths and Dr Anita Pye and Mrs. Rebecca Bray for assistance with patient recruitment and  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

the Alpha-1 Foundation and a non-commercial grant from CSL Behring for funding this work.




FIGURE 1.  
FEV1/FVC ratio is plotted against MMEF % predicted. Each point represents data from a single patient (n=196) with all measurements taken on the same day. Groups 1, 2 and 3 are highlighted.

197x150mm (96 x 96 DPI)





FIGURE 2.

The charts show median, IQR and minimum/maximum bars for total SGRQ scores (A) and individual domain scores for activity (B), disease impact (C) and symptoms (D) for Groups 1, 2 and 3. P values are shown for each comparison.

104x143mm (96 x 96 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



As for figure 2A


104x143mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



As for figure 2A

104x143mm (96 x 96 DPI)



As for figure 2A

104x143mm (96 x 96 DPI)






FIGURE 3.

The chart shows median, IQR and minimum/maximum bars in the annual change in FEV1 (expressed as % predicted) for Groups 1, 2 and 3. Values were calculated from the regression line of annual serial measurements of 4 data points or more. A lower value indicates a faster rate of decline. The median FEV1 percent predicted decline in Group 1 was approximately zero, suggesting these patients experienced an FEV1 decline in keeping with that expected with age alone. Patients within Groups 2 and 3 experienced a decline in FEV1 greater than seen with age alone, suggesting disease progression.

128x138mm (96 x 96 DPI)




FIGURE 4.

The chart shows mean lung density (HU) versus MMEF % predicted. Each point represents data from a single patient (n=109). Patients with reduced MMEF (<80% predicted) but a lung density above that typical of macroscopic emphysema (>950 HU) are shown by the shaded area.

207x140mm (96 x 96 DPI)